Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: Association with intravitreal injection treatment profiles in real-world setting
Acta Ophthalmologica Nov 23, 2019
Brito P, et al. - Researchers conducted the study for investigating the role of serum levels of pro-inflammatory factors in the identification of persistent diabetic macular oedema (DME) cases with the limited anatomic response to anti-VEGF, as well as analyzing possible predictive connections between serum factors and intravitreal treatment profiles. DME cases have been treated with monthly bevacizumab. In total, 58 cases have been involved receiving a mean of 7.23 ± 1.55 IVI in 12 months, resulting in a significant improvement of visual acuity and central foveal thickness. According to findings, serum markers of microvascular damage (high-sensitivity C-reactive protein, homocysteine and creatinine) were linked to a higher frequency of IVI due to persistent DME, indicating a role for such biomarkers in the identification of limited responders to anti-VEGF monotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries